Effects of pretreatment of Hep G2 Cells with β-naphthoflavone on cytotoxicity of propranolol and its active metabolite 4-hydroxypropranolol

Journal of Health Science

Volumn 49, Issue 4, 2003, Pages 292-297

  Miyano, Junko ^a   Motoyama, Harumi ^a   Fukuoka, Masako ^a   Yamamoto, Shigeo ^a   Narimatsu, Shizuo ^a   Ogura, Kenichiro ^b   Watabe, Tadashi ^b,c   Nishimura, Masuhiro ^d   Ueda, Nobuhiko ^d   Naito, Shinsaku ^d  

^a OKAYAMA UNIVERSITY   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

^d OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

4 hydroxypropranolol; Cytotoxicity; Hep G2 cell; Propranolol; Sulfation; naphthoflavone

Indexed keywords

4 HYDROXYPROPRANOLOL; 4 NITROPHENYLACETIC ACID; ACETIC ACID DERIVATIVE; BETA NAPHTHOFLAVONE; CARBOXYLESTERASE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; DIMETHYL SULFOXIDE; DRUG METABOLITE; ETHOXYRESORUFIN DEETHYLASE; LANSOPRAZOLE; PHENACETIN O DEETHYLASE; PROPRANOLOL; SULFOTRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEPG2; CENTRIFUGATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROLYSIS; LIVER CYTOSOL; LIVER MICROSOME; SULFATION;

EID: 14644433838     PISSN: 13449702     EISSN: 13475207     Source Type: Journal    
DOI: 10.1248/jhs.49.292     Document Type: Article

References (26)

1. Marathe, P. H., Shen, D. D. and Nelson, W. L. (1994) Metabolic kinetics of pseudoracemic propranolol in human liver microsomes. Drug Metab. Dispos., 22, 237-247.
2. Walle, T., Walle, U. K., Cowart, T. D., Conradi, E. C. and Gaffney, T. E. (1987) Selective induction of propranolol metabolism by smoking: Additional effects on renal clearance of metabolite. J. Pharmacol. Exp. Ther., 241, 928-933.
3. Masubuchi, Y., Hosokawa, S., Horie, T., Ohmori, S., Kitada, M., Suzuki, T. and Narimatsu, S. (1994) Cytochrome P-450 isozymes involved in propranolol metabolism in human liver microsomes: The role of CYP-2D6 as ring-hydroxylase and CYP1A2 as N-desisopropyrase. Drug Metab. Dispos., 22, 909-915.
4. Evans, G. H. and Shand, D. G. (1973) Disposition of propranolol. V. Drug accumulation and steady state concentrations during chronic oral administration in man. Clin. Pharmacol. Ther., 14, 487-493.
5. Straka, R. J., Lalonde, R. L., Pieper, J. A., Bottorff, M. B. and Mirvis, D. M. (1987) Non-linear pharmacokinetcis of unbound propranolol after oral administration. J. Pharm. Sci., 76, 521-524.
6. Bax, D. N. S., Lennard, M. S. and Tucker, G. T. (1983) Inhibition of antipyrine metabolism by beta-adrenocetor antagonists. Br. J. Pharmacol., 12, 779-784.
7. Suzuki, T., Ishida, R., Matsui, S., Masubuchi, Y. and Narimatsu, S. (1993) Kinetic analysis of metabolic inhibition between lidocaine and propranolol in rat liver microsomes. Biochem. Pharmacol., 45, 1528-1530.
8. Schneck, D. W. and Prichard, J. F. (1981) The inhibitory effect of propranolol pretreatment on its own metabolism in the rat. J. Pharmacol. Exp. Ther., 218, 575-581.
9. Shaw, L., Lennard, M. S., Tucker, G. T., Bax, N. D. S. and Woods, H. F. (1987) Irreversible binding and metabolism of propranolol by human liver microsomes - relationship to polymorphic oxidation. Biochem. Pharmacol., 36, 2283-2288.
10. Fitzgerald, D. J. and O'Donnell, S. R. (1971) Pharmacology of 4-hydroxypropranolol. Br. J. Pharmacol., 43, 222-235.
11. Masubuchi, Y., Narimatsu, S., Hosakawa, S. and Suzuki, T. (1994) Role of the CYP2D subfamily in metabolism-dependent propranolol binding to liver microsomal protein in rats. Biochem. Pharmacol., 48, 1891-1898.
12. Narimatsu, S., Watanabe, T., Mochida, M., Masubuchi, Y., Horie, T., Kumagai, Y., Cho, A. K., Imaoka, S., Funae, Y., Ishikawa, T. and Suzuki, T. (1995) Characterization of a chemically reactive propranolol metabolite that bind to microsomal proteins of rat liver. Chem. Res. Toxicol., 8, 721-728.
13. Narimatsu, S., Arai, T., Watanabe, T., Horie, T., Suzuki, T., Ishikawa, T., Tsutsui, M., Kumagai, Y. and Cho, A. K. (1997) Covalent binding of a reactive metabolite derived from propranolol and its active metabolite 4-hydroxypropranolol to hepatic microsomal proteins in the rat. Chem. Res. Toxicol., 10, 289-295.
14. Narimatsu, S., Arai, T., Masubuchi, Y., Horie, T., Hosokawa, M., Ueno, K., Kataoka, H., Yamamoto, S., Ishikawa, T. and Cho, A. K. (2001) Inactivation of Rat Cytochrome P450 2D Enzyme by a Further Metabolite of 4- Hydroxypropranolol, the Major and Active Metabolite of Propranolol. Biol. Pharm. Bull., 24, 988-994.
15. Steiner, A., Walle, U. K. and Walle, T. (1992) Induction of propranolol metabolism in the Hep G2 human hepatoma cell line. J. Pharm. Pharmacol., 44, 611-614.
16. Walle, T., Walle, U. K., Shwed, J. A., Thornburg, K. R., Mathis, C. E. and Pesola, G. R. (1994) Human phenol sulfotransferases: chiral substrates and expression in Hep G2 cells. Chem.-Biol. Interact., 92, 47-55.
17. Sinjari, T., Trnwall, U. and Darnerud, P. O. (1993) Induction of 7-ethoxyresorufin-O-deethylase (EROD) activity in mice foetuses by the PCB-congener 3,3′,4,4′-tetrachlorobiphenyl. Xenobiotica, 23, 107-114.
18. Sesardic, D., Edwards, R. J., Davies, D. S., Thomas, P. E., Levin, W. and Boobis, A. R. (1990) High affinity phenacetin O-deethylase is catalyzed by cytochrome P450d (P4501A2) in the liver of rat. Biochem. Pharmacol., 39, 489-498.
19. Forkert, P. G. and Lee, R. P. (1997) Metabolism of ethyl carbamate by pulmonary cytochrome P450 and carboxylesterase isozymes: Involvement of CYP2E1 and hydrolase A. Toxicol. Appl. Pharmacol., 146, 245-254.
20. Narimatsu, S., Kobayashi, N., Asaoka, K., Masubuchi, Y., Horie, T., Hosokawa, M., Ishikawa, T., Ohmori, S., Kitada, M., Miyano, J., Kataoka, H. and Yamamoto, S. (2001) High-performance liquid Chromatographic analysis of the sulfation of 4-hydroxypropranolol enantiomers by monkey liver cytosol. Chirality, 13, 140-147.
21. Lowry, O. H., Rosebrough, N. J., Fair, A. L. and Randall, R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193, 265-275.
22. Runge, D., Kohler, C., Kostrubsky, V. E., Jager, D., Lehmann, T., Runge, D. M., May, U., Stolz, D. B., Strom, S. C., Fleig, W. E. and Michalopoulos, G. K. (2000) Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes. Biochem. Biophys. Res. Commun., 273, 333-341.
23. Masubuchi, N., Li, A. P. and Okazaki, O. (1998) An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes. Chem. Biol. Interact., 114, 1-13.
24. Ching, M. S., Bichara, N., Blake, C. L., Chabrial, H., Tukey, R. H. and Smallwood, R. A. (1996) Propranolol 4- and 5-hydroxylation and N-desisopropylation by cloned human cytochrome P4501A1 and P4501A2. Drug Metab. Dispos., 24, 692-694.
25. Rendic, S. and Di Carlo, F. J. (1997) Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev., 29, 413-580.
26. Walle, T., Otake, T., Galijatovic, A., Ritter, J. K. and Walle, U. K. (2002) Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in the human hepatoma cell line Hep G2. Drug Metab. Dispos., 28, 1077-1082.